Device and method for detecting low levels of the t 4 hormone during pregnancy
Patent Information
- Application Number
- PCT/CL2024/050088
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2024-08-08
- Publication Date
- 2024-11-14
Smart Images

Figure IMGF000034_0001 
Figure 00000038_0000 
Figure 00000038_0001
Abstract
Description
[0001] DEVICE AND METHOD FOR DETECTING LOW LEVELS OF THE T4 HORMONE DURING PREGNANCY
[0002] TECHNICAL FIELD
[0003] The present invention relates, in general, to methods of diagnosis and detection of diseases such as immunoassays, and in particular to a device, a kit that uses it and a method for detecting low levels of the T4 hormone in urine during pregnancy, using for this purpose a colorimetric lateral flow competitive assay with monoclonal antibodies.
[0004] BACKGROUND OF THE INVENTION
[0005] The thyroid hormones thyroxine or tetraiodothyronine (T4) and 3,3,5 th- iodothyronine (T3) are essential for the proper development of the fetus during gestation. Deficiency of the T4 hormone during pregnancy is strongly correlated with cognitive damage in offspring (Lavado-Autric et al. Early maternal hypothyroxinemia alters histogenesis and cerebral cortex cytoarchitecture of the progeny. J Clin Invest. 2003. 1 1 1 (7):1073-82; Ghassabian etal. Downstream effects of maternal hypothyroxinemia in early pregnancy: nonverbal IQ and brain morphology in school-age children. J Clin Endocrinol Metab. 99(7):2383-90; Maternal thyroid hormone insufficiency during pregnancy and risk of neurodevelopmental disorders in offspring: A systematic review and metaanalysis. Cognitive consequences have been described ranging from attention deficit to low IQ, autism, schizophrenia and mental retardation.Reduced levels of T4 have been observed mainly in two thyroid pathologies: hypothyroidism and hypothyroxinemia.
[0006] Hypothyroidism is clinically characterized by a decrease in serum T4 and T3 levels associated with an increase in thyroid-stimulating hormone (TSH). Hypothyroxinemia, on the other hand, is characterized by a decrease in T4 only and normal levels of T3 and TSH. Both conditions have a high prevalence worldwide (Negro et al. Hypothyroxinemia and pregnancy. Endocr Pract. 201 1. 17(3):422-9; López-Muñoz et al. Hypothyroidism and isolated hypothyroxinemia in pregnancy, from physiology to the clinic. Taiwan J Obstet Gynecol. 2019. 58(6):757-763; Osinga et al. TSH and FT4 Reference Interval Recommendations and Prevalence of Gestational Thyroid Dysfunction: Quantification of Current Diagnostic Approaches.
[0007] On the other hand, the high prevalence of hypothyroidism and hypothyroxinemia during pregnancy occurs primarily because the maternal thyroid gland is under physiological stress, as it must supply T4 to both the developing fetus and the pregnant woman's own needs. During pregnancy, the fetus primarily depends on maternal T4, as this hormone is able to efficiently cross the placental barrier. Dependence on maternal T4 occurs 100% of the time until the 20th week of gestation. This is because the child's hypothalamic-pituitary-thyroid axis is still immature for the proper synthesis of thyroid hormones. In fact, it has been described that the regulated secretion of thyroid hormones by the fetus occurs after the thirty-sixth week of gestation (Forhead AJ, Fowden AL. Thyroid hormones in fetal growth and prepartum maturation. J Endocrinol. 2014. 221 (3):R87-R103; Moog et al.Influence of maternal thyroid hormones during gestation on fetal brain development. Neuroscience. 2017. 342:68-100; Eng L, Lam L. Thyroid Function During the Fetal and Neonatal Periods. Neoreviews. 2020. 21 (1):e30-e36).
[0008] Furthermore, the mother's T4 production must increase because during pregnancy not only is there a greater demand for this hormone, but also because the mother's body volume and plasma protein concentration increase. Therefore, T4 levels during pregnancy must be monitored to avoid an imbalance that is harmful to the child.
[0009] Currently, for the management of hypothyroidism in pregnant women, it is indicated that clinical monitoring of maternal thyroid function should be performed by determining the pregnant woman's TSH level after the first trimester of pregnancy, to rule out the risk of developing hypothyroidism due to pregnancy (Alexander et al. Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum. Thyroid. 2017. 27(3):315-389; Osinga et al. TSH and FT4 Reference Interval Recommendations and Prevalence of Gestational Thyroid Dysfunction: Quantification of Current Diagnostic Approaches. J Clin Endocrinol Metab. 2024. 109(3):868-878). However, this check-up occurs late in the gestation period and is insufficient, since the most important processes for the formation of the fetus's central nervous system (CNS) have occurred in the first 20 weeks.
[0010] On the other hand, measuring TSH alone, without performing a T4 test, carries a risk of missing the diagnosis of hypothyroxinemia. Hypothyroxinemia is asymptomatic for pregnant women, which is why it is very common for pregnant women who do not present symptoms during their first pregnancy checkup to miss this condition and not receive an early diagnosis.
[0011] Therefore, it is desirable to have means to monitor T4 levels, preferably during the first month of pregnancy, with monitoring of this hormone levels every two months during the first six months of pregnancy.
[0012] The state of the art describes different alternative methods currently used for this purpose, to detect low levels of the T4 hormone in blood or urine samples from pregnant women.
[0013] For example, document RU 2 31 1 646 C1 describes a method for diagnosing congenital or gestational hypothyroidism in pregnant women, enabling early detection and prevention of the risks associated with low levels of free T4 in the blood. This method involves calculating the ratio of free T3 and free T4 hormones from a blood sample. If the free T3 / free T4 ratio is greater than 0.28, the woman has minimal thyroid dysfunction and should therefore begin treatment to increase her thyroid hormone levels. The hormone concentrations are analyzed using a radioimmunoassay.
[0014] For its part, document IN202021036831 describes a lateral flow test kit for the detection of hormone levels in a blood sample, in which one end of said strip contains a sample pad comprising at least one blood separator; a conjugate pad located upstream of said sample pad, wherein said conjugate pad comprises a plurality of anti-hormone antibody bioconjugates, or fragment thereof, and gold nanoparticles; an absorbent pad located at the other end of said test strip; and a reaction pad comprising a test zone and a control zone, located between said conjugate pad and the absorbent pad, wherein said hormone is at least one hormone selected from a group consisting of thyroid stimulating hormone (TSH), thyrothyronine (T3) and thyroxine (T4), or fragments thereof.
[0015] Finally, US 2002 / 076827 A1 describes a method for diagnosing a thyroid condition in a subject comprising determining the concentration of thyroid-stimulating hormone (TSH) in a urine sample. The method is based on analyzing the sample by a method other than a radioimmunoassay and comparing the concentration of thyroid-stimulating hormone with a urinary concentration of thyroid-stimulating hormone in a normal subject; wherein: i) if the concentration of thyroid-stimulating hormone in the sample from the subject is higher than the urinary concentration of thyroid-stimulating hormone in a normal subject, said subject is diagnosed with hypothyroidism; while i) if the concentration of thyroid-stimulating hormone in the sample from the subject is lower than the urinary concentration of thyroid-stimulating hormone in the normal subject, said subject is diagnosed with hyperthyroidism.
[0016] From the prior art it can be deduced that there is no kit and method specifically designed to detect low levels of the T4 hormone in urine samples of pregnant women, which would facilitate self-detection of this pathology from the first weeks of pregnancy, through a simple home-use test, as well as providing the possibility of monitoring the levels of this hormone throughout the pregnancy, in an easy and simple manner, without having to occupy additional hospital facilities and materials for this type of diagnosis. BRIEF DESCRIPTION OF THE FIGURES
[0017] FIG. 1 shows a design of the T4 detection prototype. FIG. 1A shows an external photograph of a prototype based on a cassette-type pregnancy test model. FIG. 1B shows the internal design of the test strip.
[0018] FIG. 2 shows representative photographs of the laboratory-assembled dipstick flow test. FIG. 2A shows the loading of buffer volume at a pH simulating human urine. FIG. 2B shows the buffer solution passing through the absorbent pad to the nitrocellulose strip (black circle). FIG. 2C shows the color change to blue indicative of buffer solution flow to the bromophenol line (black circle).
[0019] FIG. 3 shows representative photographs showing the time at which 500 pl of buffer T=0 is added (FIG. 3A) and the final run time T=5 min, color control band (FIG. 3B).
[0020] FIG. 4 shows that urinary T4 concentration directly correlates with serum T4 concentration.
[0021] FIG. 5 shows the detection of T4-BSA by ELISA using a commercial anti-T4 monoclonal antibody.
[0022] FIG. 6 shows a representative photograph of a dot-blot assay performed on a nitrocellulose matrix for the detection of T4-BSA.
[0023] FIG. 7 shows a representative schematic of the anti-T4 prototype proposed in the present invention. The black arrow shows the direction of sample flow.
[0024] FIG. 8 shows a dot blot using anti-T4 antibody bound to colored latex beads in the detection of T4-BSA. FIG. 8A shows the staining of the aggregated latex beads in the dot blot. FIG. 8B shows the dot blot detection of the immunocomplex formed by the binding of anti-T4 antibody to colored latex beads and the T4-BSA conjugate (spots 1, 2, and 3).
[0025] FIG. 9 shows the color detection for different dilutions of the colored latex beads on the antibody pad bound to these beads. FIG. 10 shows a flow test of the colored latex beads at concentrations of 25 to 50%.
[0026] FIG. 1 1 shows a flow test with the prototype stick type (cassette type pregnancy test model) of FIG. 1 . T: time.
[0027] FIG. 12 shows a dot blot measuring the signal intensity generated by the binding of different amounts of the anti-T4-B antibody to a fixed amount of T4-BSA. A proportional relationship between the amount of antibody (from 5 pg to 50 pg) and the intensity of the binding signal is shown.
[0028] FIG. 13 shows the results of a competition assay between T4-BSA and T4S for binding to different amounts of anti-T4 antibody bound to colored latex beads.
[0029] FIG. 14 shows the results of determining the minimum amount of T4S required to block antibody binding.
[0030] FIG. 15 shows the results of determining the amount of anti-T4-B antibody that allows discriminating lower levels from levels equal to or greater than 15 ng of T4.
[0031] FIG. 16 shows the results of the determination between 10 pg and 40 pg of anti-T4-B antibody which establishes positive correlation in the detection of 15 ng of T4-BSA using 0.3 pm colored latex spheres.
[0032] FIG. 17 shows the results of the determination of 10 pg of anti-T4-B antibody to discriminate levels less than 15 ng of T4 from amounts greater than 15 ng of T4, using 0.3 pm colored latex spheres.
[0033] FIG. 18 shows the results of the determination of 5 pg of anti-T4-B antibody to discriminate levels less than 15 ng of T4 from amounts greater than 15 ng of T4, using 0.3 pm colored latex spheres.
[0034] FIG. 19 shows the results of a 10 pg anti-T4-B agglutination assay with 15 ng T4-BSA in 100 µl wells for naked eye visual identification of antigen / antibody immune complex formation. FIG. 20 shows the results of anti-T4-B antibody discrimination assays by plate agglutination to discriminate amounts greater than 15 ng T4-BSA.
[0035] FIG. 21 shows the results of determining the amount of anti-T4-B antibody and the incubation volume required to discriminate levels greater than 15 ng of T4.
[0036] FIG. 22 shows the validation of the device and method for T4 deficiency detection by competition is effective in indicating that urine samples from pregnant women have normal T4 levels.
[0037] SUMMARY OF THE INVENTION
[0038] The present invention provides a device, a kit containing it, and a method specifically designed for the detection of low levels of the hormone T4 in urine samples from pregnant women. This device allows for self-detection of this condition from the first weeks of pregnancy and enables easy and simple monitoring of T4 levels throughout the entire pregnancy period, without the need for additional hospital facilities and materials for this type of diagnosis.
[0039] A first object of protection of the present invention is a device for detecting levels below normal values of the hormone thyroxine (T 4) during pregnancy in a urine sample, said device including:
[0040] (a) a test strip made of an absorbent material that includes along its length the reagents necessary to detect levels of the T4 hormone below a threshold; and
[0041] (b) means for providing a visible readout in the form of a detection label at levels of the T4 hormone below said threshold; said reagents of the device including: a conjugate of the T4 hormone with bovine serum albumin (T4-BSA); a primary monoclonal antibody against the T4 hormone (anti-T4) bound to latex beads; and wherein the means for providing a visible readout in the form of a detection label at levels of the T4 hormone below said threshold is the formation of an immunocomplex between the primary monoclonal antibody against the T4 hormone (anti-T4) bound to latex beads and the T4 hormone present in the T4-BSA conjugate.
[0042] In a preferred embodiment of the present invention, the device for detecting levels below normal values of the T4 hormone in pregnant women includes said T4-BSA conjugate in an amount between 10-15 ng in the test strip that it contains.
[0043] In another preferred embodiment of the present invention, the device sets the threshold for the detection of this pathology in the urine of pregnant women at T4 levels below 30 ng / ml, the working volume being 0.5 ml (15 ng / 0.5 ml) for a urine sample.
[0044] In another preferred embodiment of the present invention, the primary anti-T4 monoclonal antibody that forms part of the claimed device detects up to 20 ng / ml of the T4 hormone in the pregnant woman's urine sample, equivalent to 10 ng of the T4 hormone in 0.5 ml of the urine sample. For detection, in addition, in another preferred embodiment of the invention, said primary anti-T4 monoclonal antibody is bound to latex spheres in a ratio of 2 mg / ml to 1% w / v of spheres, and said latex spheres to which the anti-T4 monoclonal antibody binds are selected from the group consisting of colored, carboxylated, fluorescent and paramagnetic latex microspheres, and have a size of 0.3 pm.
[0045] In yet another preferred embodiment of the present invention, the primary anti-T4 monoclonal antibody bound to the latex beads is present on the test strip of the device at an amount of 5-10 pg.
[0046] Another object of the present invention is a kit for detecting levels below normal values of the T4 hormone during pregnancy in a urine sample, said kit comprising: (a) a device as previously described in all its embodiments, and
[0047] (b) written instructions on how to add the urine sample to the test strip of said device, and how to interpret the results observed from the appearance of the detection mark in the test zone of said test strip.
[0048] Another additional object of the invention is an "ex vivo" method for detecting levels below normal values of the T4 hormone in a urine sample from a pregnant woman, said method comprising the steps or steps of:
[0049] (a) provide a device or kit as described in any of the previously described embodiments;
[0050] (b) add the urine sample to be analyzed to the test strip of said device; and
[0051] (c) read the result visible on the strip as a detection mark in the test area of said strip, which is indicative that the pregnant woman from whom said urine sample was obtained has T4 hormone levels below 30 ng / ml.
[0052] In a preferred embodiment of the method of the present invention, 0.5 ml of the urine sample to be analyzed is added to the test strip.
[0053] A final object of the present invention is a method of manufacturing a device for detecting levels below normal values of the T4 hormone during pregnancy, said method comprising the steps or stages of:
[0054] (a) provide a test strip made of an absorbent material,
[0055] (b) placing along the length of the test strip the reagents necessary to detect levels of the T4 hormone below a threshold; and
[0056] (c) providing means for visible reading as a detection mark at levels of the T4 hormone below said threshold; where the reagents included in said test strip comprise: - a conjugate of the T4 hormone with bovine serum albumin (T4-BSA);
[0057] - a primary monoclonal antibody against the T4 hormone (anti-T4) bound to latex beads; and where the means for providing the visible readout in the form of a detection label at levels of the T4 hormone below said threshold is the formation of an immunocomplex between the primary monoclonal antibody against the T4 hormone (anti-T4) bound to latex beads and the T4 hormone present in the T4-BSA conjugate.
[0058] In a preferred embodiment of the manufacturing method of the device of the invention, the T4-BSA conjugate is added to the test strip at an amount of 10-15 ng.
[0059] In another preferred embodiment of the manufacturing method of the device of the invention, said primary anti-T4 monoclonal antibody is mixed with said latex spheres in a ratio of 2 mg / ml to 1% w / v of spheres. In an equally preferred embodiment of the invention, these latex microspheres are colored, carboxylated, paramagnetic, or fluorescent, among other alternatives for their detection.
[0060] In yet another preferred embodiment of the manufacturing method of the device of the invention, the latex spheres to which said primary anti-T4 monoclonal antibody is bound are selected for a size equal to or less than 0.3 µm and preferably, said primary anti-T4 monoclonal antibody bound to the latex spheres is added to the test strip at an amount of 5-10 µg.
[0061] The preferred embodiments of the invention mentioned above are provided only as examples of possible particular embodiments of the inventive concept that it encompasses; however, they should not be considered in any case to restrict the scope of protection of the intellectual creation developed by the applicant, and which will only be defined by the subject matter included in the set of claims that form part of this patent application. DETAILED DESCRIPTION OF THE INVENTION
[0062] As previously described, the invention includes a medical device in the form of a test for home or self-diagnosis use, for detecting deficient levels of the thyroid hormone thyroxine (T4) in biological samples from a pregnant patient, particularly in urine samples. The invention also includes a kit including said device and a method for detecting levels of the T4 hormone below normal levels in the pregnant patient throughout the gestational period, as well as a method of manufacturing said medical device.
[0063] The device is intended for early detection of deficient thyroxine levels during pregnancy, which could lead to the prevention of neurodevelopmental disorders in infants. As described, low thyroxine levels during pregnancy can have consequences for the infant's subsequent neurodevelopment, including an increased risk of communication disorders, specific learning disabilities (SLD), autism spectrum disorder (ASD), attention deficit disorder (ADD and ADHD), among other neurodevelopmental disorders.
[0064] The device of the invention was specifically designed for the detection of low levels of T4 in urine.
[0065] The device of the invention is based on a competitive lateral flow immunoassay, which uses a test strip made of absorbent material, such as cellulose or its derivatives, in a preferred embodiment of the invention made of nitrocellulose, where the result of the reaction between the sample and the reagents included in the test strip is evidenced by the appearance of a mark in the test area of said strip, which is visibly detected by the user. Basically in this type of tests, these strips contain pads, usually also composed of fiberglass, where the reagents that react with the biomarkers that are present in the sample to be analyzed are placed. If the test area shows the appearance of such a mark, for example, the appearance of a colored line, fluorescence, etc., the user will be able to detect the presence of the marker in the sample, in this particular case, it will detect the T4 hormone at the concentration that was established as the threshold to be able to detect it.
[0066] That is, according to the design of the device object of the present invention (FIG. 1 ), the test strip of the device contains a first pad (1 ) where the urine sample to be analyzed would be placed, a second pad (2) where the primary anti-T4 monoclonal antibody is placed bound to the latex spheres, then the test line (3) is framed which contains the antigen-protein conjugate (T4 hormone-BSA), and finally the control line (4). In this way, once the sample under analysis is placed on its corresponding pad, it rises by capillarity and first reaches the area where the primary anti-T4 antibody (2) is located. This antibody, as explained, is bound to latex spheres, which when added together allow a mark to be seen with the naked eye on the test strip.
[0067] Antibody aggregation will occur at the detection mark or test line (3) where the T4 hormone bound to albumin (T4-BSA conjugate) is located. This will occur when the urine sample contains an amount of T4 lower than normal levels in pregnant women, where normal values in pregnant women's urine samples are between 30 - 60 ng / ml. On the other hand, if the pregnant woman's urine has normal T4 levels, then all of the antibody bound to the latex spheres found on the first pad (1) will bind to the T4 present in the urine sample and will not bind to the T4-BSA conjugate, and therefore the corresponding detection band or mark visible to the naked eye will not be observed on the test line (3).
[0068] Finally, the appearance of a line or mark on the control line (4) of the test strip will indicate that the flow of the sample on the test strip has occurred correctly.
[0069] The device thus designed allows the test result to be observed by visualizing reaction marks, in the form of lines or bands, where the presence of two colored lines, when using colored latex spheres, is indicative of thyroxine deficiency (values below normal in pregnant women) in the sample, and the presence of a single colored line is indicative of normal levels of thyroxine in the sample, where the two reaction lines will correspond to the test line and the flow control line.
[0070] EXAMPLES OF IMPLEMENTATION
[0071] Example 1: Design of a prototype device for detecting T4 hormone levels
[0072] The prototype of the present invention was based on the internal structure of a pregnancy test that uses the competitive lateral flow chromatography technique in cassette format (FIG. 1 A). The device (FIG. 1 B) is formed by a 2-layer glass fiber pad of 4.2 cm x 0.6 cm (1) that receives the sample. Then a 0.5 cm x 0.6 cm glass fiber pad where the anti-T4 primary antibody bound to latex spheres is located (2). Then a 2 cm x 0.6 cm nitrocellulose membrane where the T4-BSA conjugate is placed (3) and finally the 3 cm x 0.6 cm flow control pad (4). The total size of the device is 9.4 cm x 0.6 cm.
[0073] To perform the first tests, anti-T4 monoclonal antibodies from the trademark Mybiosource (CAT: MBS568391) were used at a stock concentration of 6.8 mg / ml and the mouse anti-human monoclonal anti-T4 antibody from the trademark Mybiosource (CAT: MBS531620) at a stock concentration of 6.1 mg / ml, in addition to a T4-BSA conjugated reagent (BSA conjugated Thyroxine Hapten) from the trademark Mybiosource (CAT: MBS5308085), in 1 mg format. The antibody was deposited on the strip in a range of 5 - 10 pg, equivalent to a range of 0.1666 pg / mm 2 at 0.3333 pg / mm 2 .
[0074] The designed test strip is incorporated into a plastic cassette to perform flow tests. Briefly, a section of nitrocellulose containing a bromophenol blue solution is added, which acts as an indicator of flow and the correct functioning of the strip assembled in the laboratory. Flow detection is detected by the color change when using a solution with a pH equal to that of urine. FIGS. 2A, 2B, and 2C show that correct flow occurred when using a 0.5 ml urine sample volume. Regarding time, it was determined that, in the closed plastic cassette, 5 minutes are required for 0.5 ml of solution to flow to the bromophenol line and for the color change to occur (FIGS. 3A and 3B).
[0075] Previous laboratory studies allowed for the determination of T4 in urine samples from pregnant women. The serum total T4 (fR) value was also determined and correlated with the data obtained in urine, which was performed using ELISA. The results obtained are shown in FIG. 4.
[0076] In FIG. 4, it is observed that the fR content in urine presents the same pattern as that observed in the patients' serum, so it is possible to use the determination in urine as an indicator of the thyroid function of pregnant women.
[0077] To prepare a competitive detection test for T4, the hormone T4 was conjugated to the protein bovine serum albumin (BSA). This reagent was called T4-BSA conjugate and was used in the test strip so that it could compete with the T4 present in the urine sample for the anti-T4 antibody.
[0078] The first step was to determine whether this antibody detects the T4-BSA conjugate and its sensitivity to binding. To this end, ELISA studies were performed using a commercial anti-T4 antibody (Mybiosource, CAT: MBS568391). The results obtained are shown in FIG. 5. In these assays, the antibody concentration used was 0.068 pg / pl. The result obtained was the detection of 1, 2, and 10 pg of T4-BSA in a volume of 100 pl.
[0079] The second step was the detection of T4-BSA on a nitrocellulose matrix (the same matrix used in the test strip) using a dot-blot detection model. To do this, the T4-BSA conjugate was first locally bonded to the nitrocellulose strip by depositing small drops containing different concentrations of T4-BSA (FIG. 6). Once the drops had dried on the matrix, 0.54 pg of the primary anti-T4 antibody was added. The results for the tested conditions are shown in FIG. 6, where:
[0080] Point 1: 1 pg of T4-BSA
[0081] Point 2: 2 pg of T4-BSA Point 3: 10 pg of T4-BSA
[0082] Point 4: 1 pg of BSA
[0083] Point 5: 10 pg of BSA
[0084] Point 6: Primary anti-T4 antibody (1:100)
[0085] Point 7: Secondary anti-T4 antibody (1:10,000)
[0086] Point 8: Empty control.
[0087] It was observed that the anti-T4 antibody was able to detect a minimum of 10 pg of BSA-T4 (FIG. 6).
[0088] Because T4 hormone concentrations in urine vary between 3 and 5 pg / dl and the strip of the present invention must absorb approximately 0.5 ml, the possibility of using a larger amount of antibody was evaluated. Based on these results, it was determined that a larger amount of anti-T4 antibody should be placed on the test strip, this amount being determined to be between 1 and 10 pg.
[0089] In the proposed test scheme (FIG. 7), the T4-BSA reagent is adhered to the strip 1 cm from the control line on the nitrocellulose membrane, the anti-T4 antibody is located on the corresponding pad (2), between the sample pad (1) and the test line (3) that includes the T4-BSA reagent, in an order that follows the direction of sample flow through the control line (4) to the absorbent pad (5). The test then consists of the T4 present in the urine competing with the T4-BSA adhered to the strip for binding to the anti-T4 antibody. If the concentration of T4 in the pregnant woman is normal, the anti-T4 antibody on its corresponding pad will bind to the T4 in the urine and there will be no binding to the T4-BSA reagent, so only the appearance of the positive control line of the test will be observed.On the contrary, if the concentration of T4 in urine is less than 30 ng / ml, free anti-T4 antibody will remain which, due to the flow, will be able to adhere to the T4-BSA reagent attached to the strip, generating the corresponding detection mark on the test line (3). This line will be indicative of T4 deficiency in urine. The detection mark will be observed because the anti-T4 antibody will be covalently linked to colored latex spheres that allow the visualization of the reaction of formation of the T4 antigen-anti-T4 antibody immunocomplex. Anti-T4 bound to latex spheres was covalently coupled using two-step EDC / Sulfo NHS as described by the manufacturer (Microsphere Coupling — Two-step EDC / Sulfo NHS Covalent Coupling Procedure for Estapor® Carboxyl-modified Dyed Microspheres. Merck KGaA, Darmstadt, Germany. 2022. https: / / www.emdmillipore.com / Web-US-Site / en_CA / - / USD / ShowDocument- Pronet?id=201507.096) (Raysyan et al.Development of a latex particles-based lateral flow immunoassay for group determination of macrolide antibiotics in breast milk. J Pharm Biomed Anal. 2020. 189:1 13450).
[0090] To more accurately determine the amount of T4 that can be detected by the anti-T4 antibody, sensitivity studies of T4-BSA detection (1, 2, and 10 pg) were performed with the anti-T4 (primary) antibody bound to the colored latex beads. It is important to note that for binding studies, binding must be revealed visually, therefore, it is necessary to use a secondary antibody that detects the presence of anti-T4. This secondary antibody is only used experimentally for the study and will not be used in the final detection system since binding will be visualized by the agglutination of the beads. A representative photograph of a dot blot using different amounts of anti-T4 antibody is shown in FIGS. 8A and 8B, including the following assay conditions:
[0091] Point 1: 2 pg of anti-T4 antibody bound to colored latex spheres.
[0092] Point 2: 4 pg of anti-T4 antibody bound to colored latex spheres.
[0093] Point 3: 20 pg of anti-T4 antibody bound to colored latex spheres.
[0094] Point 4: Only colored latex spheres
[0095] Item 5: Primary anti-T4 antibody only (2 pg)
[0096] Point 6: Anti-T4 secondary antibody only (1:10,000)
[0097] Subsequently, the minimum concentration of latex spheres required to display color on the corresponding pad was determined. FIG. 9 shows a photograph with sections of the pad containing different dilutions of the latex spheres. The appropriate dilution to detect color was determined to be 0.25% with respect to the original solution of latex spheres, which are at 1%. The latex sphere flow tests were then performed using different dilutions of the spheres on the test strip. The concentrations tested for this assay were 0.25%, 0.30%, 0.40%, and 0.50%. It was observed that the latex spheres were retained on the conjugated pad regardless of the dilution (FIG. 10).
[0098] Flow tests were performed on the test strip for the prototype stick. Volumes of 500 pl and 1000 pl were used. FIG. 11 shows that, in both cases, there is a flow of buffer and latex spheres. The flow test was performed on the test strip contained in the plastic stick; when 1000 pl was added, it was observed that the buffer flowed; however, the detection mark was not detected on the latex spheres.
[0099] Example 2: Correlation test between the concentration of anti-T4 antibody and the intensity of the reaction signal.
[0100] Before testing the urine samples, the relationship between the amount of anti-T4 antibody bound to the 2 µm latex beads (hereafter referred to as anti-T4-B) and the detection of 15 ng of membrane-bound T4-BSA was first assessed. FIG. 12 shows a positive correlation between the higher the amount of anti-T4-B antibody and the higher the intensity of the binding visualized in the dot-blot assay. No differences in signal intensity were observed between concentrations of 30 µg and 50 µg of anti-T4-B antibody. This may be because saturation of antibody binding to the T4-BSA site had been reached.
[0101] In particular, between 5 pg and 30 pg of anti-T4-B antibody, there was a positive correlation with the intensity of the binding signal to 15 ng of T4-BSA. The binding intensity of different amounts of anti-T4-B antibody to 15 ng of T4-BSA was analyzed using dot-blot assays. The conditions used in this assay were:
[0102] Point 1: 15 ng of T4-BSA + 5 pg of the primary anti-T4-B antibody + secondary anti-T4 antibody. Point 2: 15 ng of T4-BSA + 10 pg of the primary anti-T4-B antibody + secondary anti-T4 antibody.
[0103] Point 3: 15 ng of T4-BSA + 15 pg of the primary anti-T4-B antibody + secondary anti-T4 antibody.
[0104] Point 4: 15 ng of T4-BSA + 20 pg of the primary anti-T4-B antibody + secondary anti-T4 antibody.
[0105] Point 5: 15 ng of T4-BSA + 30 pg of the primary anti-T4-B antibody + secondary anti-T4 antibody.
[0106] Point 6: 15 ng of T4-BSA + 50 pg of the primary anti-T4-B antibody + secondary anti-T4 antibody.
[0107] Point 7: 1 pg of T4-BSA + 20 pg of the primary anti-T4-B antibody + secondary anti-T4 antibody.
[0108] Point 8: 2 pL of the anti-T4-B primary antibody + anti-T4 secondary antibody.
[0109] Point 9: 1 pL of the anti-T4 secondary antibody (335 ng).
[0110] Point 10: 1 pg of BSA + 20 pg of the primary anti-T4-B antibody + secondary anti-T4 antibody.
[0111] Points 1 to 6 corresponded to the different concentrations of the primary anti-T4-B antibody tested (5 pg, 10 pg, 15 pg, 20 pg, 30 pg, and 50 pg); points 7 to 9 are positive controls, where at point 7 there is excess T4-BSA that is recognized by the anti-T4 antibody bound to beads; at point 8, the primary anti-T4-B antibody was stuck to the membrane; and at point 9, the secondary anti-T4 antibody, used as a positive control, was stuck to the membrane. Point 10 corresponds to a negative control.
[0112] Example 3: Competition essay.
[0113] Once the specific binding of the anti-T4-B antibody to the T4-BSA conjugate attached to the nitrocellulose was verified by dot blotting, the competition assays were performed. In the first competition assay, 15 ng of T4-BSA bound to the nitrocellulose was used, and 10 pg, 15 pg, and 20 pg of the anti-T4-B antibody were incubated with or without 7.5 ng of T4 in solution (T4S). In this assay, the anti-T4-B antibody was first incubated with T4S for 5 minutes and then incubated with the membrane containing T4-BSA. The conditions tested in this test were:
[0114] Point 1: 15 ng of T4-BSA + 10 pg of anti-T4-B primary antibody + anti-T4 secondary antibody.
[0115] Point 2: 15 ng of T4-BSA + 15 pg of anti-T4-B primary antibody + anti-T4 secondary antibody.
[0116] Point 3: 15 ng of T4-BSA + 20 pg of anti-T4-B primary antibody + anti-T4 secondary antibody.
[0117] Point 4: 1 pg of BSA + 20 pg of anti-T4-B primary antibody + anti-T4 secondary antibody.
[0118] Point 5: 1 pl of the anti-T4 secondary antibody (335 ng) + 0.1% BSA in TBS-T (TRIS buffered saline).
[0119] Point 6: 2 pl of the anti-T4-B primary antibody (20 pg) + 0.1% BSA in TBS-T + anti-T4 secondary antibody.
[0120] Point 7: 15 ng of T4-BSA + 10 pg of anti-T4-B primary antibody + 7.5 ng of T4 + anti-T4 secondary antibody.
[0121] Point 8: 15 ng of T4-BSA + 15 pg of anti-T4-B primary antibody + 7.5 ng of T4 + anti-T4 secondary antibody.
[0122] Point 9: 15 ng of T4-BSA + 20 pg of anti-T4-B primary antibody + 7.5 ng of T4 + anti-T4 secondary antibody.
[0123] Point 10: 1 pg of BSA + 20 pg of anti-T4-B primary antibody + 7.5 ng of T4 + anti-T4 secondary antibody.
[0124] Point 11: 1 pl of anti-T4 secondary antibody (335 ng) + 0.1% BSA in TBS-T + 7.5 ng of T4.
[0125] Point 12: 2 pl of anti-T4-B primary antibody 20 pg + 0.1% BSA in TBS-T + 7.5 ng T4 + anti-T4 secondary antibody.
[0126] In FIG. 13 it can be observed that at points 1, 2 and 3, which correspond to incubations without T4S, the binding of the anti-T4-B antibody to the T4-BSA conjugate can be observed, and that this binding increases with the increase in the amount of antibody; at points 7, 8 and 9 where the previous incubation with 7.5 ng of T4S with 10 pg, 15 pg and 20 pg of the anti T4-B antibody, decreased the intensity of the detection of 15 ng of T4-BSA. This decrease in the intensity of the signal is smaller as the amount of the anti-T4-B antibody increases, indicating that T4S competes with the T4-BSA conjugate for binding to the anti-T4-B antibody (anti-T4 antibody bound to latex spheres). However, the amount of 7.5 ng of T4S was not sufficient to displace 100% of the binding of T4-BSA to the anti-T4-B antibody, so binding of the anti-T4-B antibody to the T4-BSA conjugate was observed.
[0127] Example 4: Sensitivity curves of anti-T4 antibody bound to latex spheres.
[0128] A curve was created with increasing amounts of T4S and a fixed amount of anti-T4-B antibody. The amount of anti-T4-B antibody was 10 pg. The different assay conditions were as follows (FIG. 14):
[0129] Point 1: 15 ng of T4-BSA + 10 pg of primary anti-T4-B antibody + secondary anti-T4 antibody (335 ng).
[0130] Point 2: 15 ng of T4-BSA + 10 pg of primary anti-T4-B antibody + 1 ng of T4 + secondary anti-T4 antibody (335 ng).
[0131] Point 3: 15 ng of T4-BSA + 10 pg of primary anti-T4-B antibody + 5 ng of T4 + secondary anti-T4 antibody (335 ng).
[0132] Point 4: 15 ng of T4-BSA + 10 pg of primary anti-T4-B antibody + 10 ng of T4 + secondary anti-T4 antibody (335 ng).
[0133] Point 5: 15 ng of T4-BSA + 10 pg of primary anti-T4-B antibody + 15 ng of T4 + secondary anti-T4 antibody (335 ng).
[0134] Point 6: 15 ng of T4-BSA + 10 pg of primary anti-T4-B antibody + 20 ng of T4 + anti-T4 secondary antibody (335 ng).
[0135] Point 7: 15 ng of T4-BSA + 10 pg of primary anti-T4-B antibody + 100 ng of T4 + secondary anti-T4 antibody (335 ng). Point 8: 10 pg of ant¡-T4-B primary antibody + anti-T4 secondary antibody (335 ng).
[0136] Point 9: 15 ng of T4-BSA + 0.1 % BSA in TBS-T + anti- T4 secondary antibody (335 ng).
[0137] Point 10: 1 pg of BSA + 20 pg / 0.5 mi of anti-T4-B primary antibody + 0.1 % BSA in TBS-T.
[0138] Item 1 1 : Anti-T4 secondary antibody (335 ng) attached to the membrane.
[0139] In FIG. 14 the following can be observed: At point 1 , the anti-T4-B antibody gives a positive label for the recognition of T4-BSA on the membrane. At points 2, 3, 4, 5, 6 and 7 increasing amounts of T4S were added and all these amounts blocked the binding of the anti-T4-B antibody to T4-BSA. This result is not optimal since it does not discriminate between low amounts of T4S and normal amounts of T4S. It is observed that at concentrations less than 15 ng of T4, the binding of the anti-T4 antibody to T4-BSA is detected. This is based on the sensitivity that the detection of T4 deficiency in urine must have. That is, at amounts of T4S less than 15 ng, there should be binding of the anti-T4-B antibody to T4-BSA. Therefore, this data was indicative that the amount of anti-T4 antibody bound to the latex beads in the competition reaction should be increased.
[0140] The results of the following tested conditions are shown in FIG. 15:
[0141] Point 1 : 15 ng of T4-BSA + 40 pg of primary anti-T4-B antibody + 0 ng of T4 + anti-T4 secondary antibody (335 ng).
[0142] Point 2: 15 ng of T4-BSA + 40 pg of primary anti-T4-B antibody + 5 ng of T4 + anti-T4 secondary antibody (335 ng).
[0143] Point 3: 15 ng of T4-BSA + 40 pg of anti-T4-B primary antibody + 10 ng of T4 + anti-T4 secondary antibody (335 ng).
[0144] Point 4: 15 ng of T4-BSA + 40 pg of anti-T4-B primary antibody + 15 ng of T4 + anti-T4 secondary antibody (335 ng). Point 5: 15 ng of T4-BSA + 20 pg of primary ant¡-T4-B antibody + 0 ng of T4 + anti-T4 secondary antibody (335 ng).
[0145] Point 6: 15 ng of T4-BSA + 20 pg of primary anti-T4-B antibody + 5 ng of T4 + secondary anti-T4 antibody (335 ng).
[0146] Point 7: 15 ng of T4-BSA + 20 pg of primary anti-T4-B antibody + 10 ng of T4 + anti-T4 secondary antibody (335 ng).
[0147] Point 8: 15 ng of T4-BSA + 20 pg of anti-T4-B primary antibody + 15 ng of T4 + anti-T4 secondary antibody (335 ng).
[0148] Point 9: 0 ng of T4-BSA + 20 pg of anti-T4-B primary antibody + anti-T4 secondary antibody (335 ng).
[0149] Point 10: 15 ng of T4-BSA + 0.1 % BSA in TBS-T + anti- T4 secondary antibody (335 ng).
[0150] Point 11 : 1 pg of BSA + 20 pg of anti-T4-B primary antibody + 0.1 % BSA in TBS-T.
[0151] Point 12: Membrane-attached anti-T4 secondary antibody (335 ng).
[0152] That is, 20 pg and 40 pg of the anti-T4-B antibody were used and incubated first with 5 ng, 10 ng, and 15 ng of T4S and then with the nitrocellulose membrane to which the T4-BSA conjugate is attached. The results obtained are shown in FIG.15, where points 1 and 5 do not carry T4S so 100% binding of the anti-T4-B antibody to T4-BSA is observed; when using 40 pg of anti-T4 antibody bound to latex beads the signal is more intense compared to when 20 pg of anti-T4 antibody bound to latex beads are used; at points 2, 3, 6 and 7, when adding 5 ng and 10 ng of T4S the binding of the anti-T4-B antibody to the T4-BSA conjugate is visualized, indicating that T4 is insufficient to compete; at point 4, 15 ng of T4S is added with 40 pg of anti-T4-B antibody and it is still possible to detect the binding of the antibody to T4-BSA; At point 8, where 15 ng of T4S is added to 20 pg of anti-T4-B antibody, no binding to T4-BSA is detected, indicating that 100% competition has occurred.This result allows us to conclude that 20 pg of anti-T4-B antibody can discriminate between amounts of T4 lower than 10 ng and amounts higher than 15 ng, suggesting that it is possible to generate a device that can detect T4 deficiency in urine under specific conditions.
[0153] Example 5: Reaction visualization system using 300 nm latex particles.
[0154] In a second iteration to determine the operational parameters of the device of the invention, a search began for a better naked-eye visualization system for the binding of the anti-T4 antibody to the T4-BSA conjugate. The binding of the antibody to the latex spheres was not adequate, so different reagents were used to improve the binding, at the level of the coupling reaction of the anti-T4 antibody to the latex spheres, in order to visually observe the color mark that represents the binding of the antibody to T4-BSA. However, the result was negative, so a new detection system was included through smaller latex particles, specifically 300 nm. These latex spheres are smaller than the latex spheres used in previous iterations. Because the visualization system was modified, the following tests were performed with the new 0.3 pm latex spheres.The first step was to determine the amount of anti-T4-B required to detect BSA-T4 by dot blot. The results for the following conditions are shown in FIG. 16:
[0155] Point 1: 15 ng of T4-BSA + 40 pg of primary anti-T4-B antibody + secondary anti-T4 antibody (335 ng).
[0156] Point 2: 15 ng of T4-BSA + 20 pg of primary anti-T4-B antibody + secondary anti-T4 antibody (335 ng).
[0157] Point 3: 15 ng of T4-BSA + 15 pg of primary anti-T4-B antibody + secondary anti-T4 antibody (335 ng).
[0158] Point 4: 15 ng of T4-BSA + 10 pg of primary anti-T4-B antibody + secondary anti-T4 antibody (335 ng).
[0159] Point 5: 1 pg of BSA + 20 pg of anti-T4-B primary antibody + anti-T4 secondary antibody (335 ng). Point 6: 15 ng of T4-BSA + 0.1% BSA in TBS-T + anti-T4 secondary antibody (335 ng).
[0160] Point 7: 15 ng of T4-BSA + 20 ng of anti-T4-B primary antibody + anti-T4 secondary antibody (335 ng).
[0161] Point 8: Secondary anti-T4 antibody (335 ng) attached to membrane
[0162] In FIG. 16 the detection of 15 ng of T4-BSA from 10 pg to 40 pg of the anti-T4-B antibody can be observed, this approach shows a clear detection signal compared to the use of other sizes of latex spheres.
[0163] Example 6: Competition tests with 300 nm (0.3 pm) latex spheres.
[0164] The next step was to perform a new competition assay between T4-BSA and T4S using 10 pg of anti-T4-B antibody bound to 0.3 pm beads. 10 pg of anti-T4-B antibody was used and first incubated with 5 ng, 10 ng, 15 ng and 20 ng of T4S and then this solution containing T4S and the anti-T4-B antibody was incubated with the nitrocellulose membrane to which the T4-BSA conjugate is adhered. The results of the following conditions that were tested can be seen in FIG. 17:
[0165] Point 1: 15 ng of T4-BSA + 10 pg of anti-T4-B antibody + 0 ng of T4 + secondary anti-T4 antibody (335 ng).
[0166] Point 2: 15 ng of T4-BSA + 10 pg of anti-T4-B antibody + 5 ng of T4 + secondary anti-T4 antibody (335 ng).
[0167] Point 3: 15 ng of T4-BSA + 10 pg of anti-T4-B antibody + 10 ng of T4 + secondary anti-T4 antibody (335 ng).
[0168] Point 4: 15 ng of T4-BSA + 10 pg of anti-T4-B antibody + 15 ng of T4 + anti-T4 secondary antibody (335 ng).
[0169] Point 5: 15 ng of T4-BSA + 10 pg of anti-T4-B antibody + 20 ng of T4 + anti-T4 secondary antibody (335 ng).
[0170] Point 6: 1 pg of BSA + 10 pg of anti-T4-B antibody + anti- T4 secondary antibody (335 ng). Point 7: 15 ng of T4-BSA + 0.1 % BSA in TBS-T + anti- T4 secondary antibody (335 ng).
[0171] Point 8: 15 ng of T4-BSA + 10 pg of anti-T4-B antibody + 0.1 % BSA in TBS-T
[0172] Point 9: Secondary anti-T4 antibody (335 ng).
[0173] At point 1, which corresponds to the incubation without T4S, 100% binding of the anti-T4-B antibody to T4-BSA is observed; at points 2 to 5, corresponding to 5 ng, 10 ng, 15 ng, and 20 ng of T4S, respectively, the binding of the anti-T4-B antibody to T4-BSA is visualized. This indicates that T4S is insufficient to bind to all the anti-T4-B and therefore anti-T4-B antibody is available to bind to the T4-BSA adhered to the nitrocellulose. From this, the amount of anti-T4-B antibody had to be reduced in order to differentiate amounts of T4 less than 10 ng from amounts greater than 15 ng.
[0174] Based on the previous result, a new competition assay was performed between T4-BSA and T4S with 5 pg of anti-T4-B bound to 0.3 µm beads. The results obtained are shown in FIG. 18, for the following conditions tested:
[0175] Point 1 : 15 ng of T4-BSA + 10 pg of anti-T4-B antibody + 0 ng of T4 + anti-T4 secondary antibody (335 ng).
[0176] Point 2: 15 ng of T4-BSA + 10 pg of anti-T4-B antibody + 20 ng of T4 + anti-T4 secondary antibody (335 ng).
[0177] Point 3: 15 ng of T4-BSA + 5 pg of anti-T4-B antibody + 0 ng of T4 + anti-T4 secondary antibody (335 ng).
[0178] Point 4: 15 ng of T4-BSA + 5 pg of anti-T4-B antibody + 10 ng of T4 + anti-T4 secondary antibody (335 ng).
[0179] Point 5: 15 ng of T4-BSA + 5 pg of anti-T4-B antibody + 15 ng of T4 + anti-T4 secondary antibody (335 ng).
[0180] Point 6: 15 ng of T4-BSA + 5 pg of anti-T4-B antibody + 20 ng of T4 + anti-T4 secondary antibody (335 ng).
[0181] Point 7: 1 pg of BSA + 5 pg of anti-T4-B antibody + anti-T4 secondary antibody (335 ng). Point 8: 15 ng of T4-BSA + 0.1% BSA in TBS-T + anti-T4 secondary antibody (335 ng).
[0182] Point 9: 15 ng of T4-BSA + 5 pg of anti-T4-B antibody + 0.1% BSA in TBS-T.
[0183] Point 10: Secondary anti-T4 antibody (335 ng) attached to membrane.
[0184] From FIG. 18 it is observed that: at points 1 and 3, when using 5 pg and 10 pg of the anti-T4-B antibody in the absence of T4S, as expected, the binding of the anti-T4-B antibody to T4-BSA can be detected; at point 2, 15 ng of T4S are added to 10 pg of anti-T4-B antibody and it is still possible to detect the binding of the anti-T4B antibody to T4-BSA, this result indicates that the amount of anti-T4-B in the reaction must be decreased since we expect not to see binding at amounts equal to or greater than 15 ng T4S; At points 4, 5 and 6, 10 ng, 15 ng and 20 ng of T4S were added to 5 pg of the anti-T4-B antibody and as expected, binding of the anti-T4-B antibody to T4-BSA is observed only with 10 ng of T4, however when using 15 ng and 20 ng of T4S it is observed that the T4S competed and there is no binding of the antibody to T4-BSA because it is bound to the T4S; points 7 to 9 are negative controls and point 10 is the positive control of the secondary anti-T4 antibody signal.This result allows us to conclude that the amount of 5 pg of anti-T4-B antibody (bound to 0.3 pm latex spheres) is the most adequate to discriminate quantities less than 15 ng of T4S from quantities equal to or greater than 15 ng. Therefore, this system allowed to discriminate, by means of the binding of the anti-T4B antibody to T4-BSA, quantities of T4S less than 15 ng from quantities greater than 15 ng.
[0185] Example 7: Visual identification test for lower than normal T4 levels.
[0186] The next step was the visual identification with the naked eye of the binding of anti-T4-B to T4-BSA that is adhered to the nitrocellulose membrane. This identification is given by the agglutination of the latex spheres that are red, Merck trademark (Merck, CAT: FR180380011: K1 -030 Red COOH PS 10%; Raysyan et al. Development of a latex particles-based lateral flow immunoassay for group determination of macrolide antibiotics in breast milk. J Pharm Biomed Anal. 2020. 189:113450). The agglutination of the latex spheres occurs because they are covalently bound to the anti-T4 antibody and this by affinity bound to T4-BSA, thus forming the immunocomplex between the anti-T4 antibody and the T4-BSA conjugate, which allows visualizing the reaction by the formation of color at the site where it occurs.To perform this assay, a 96-well plate was used in which nitrocellulose membranes were placed with the T4-BSA conjugate adhered and incubated with a solution containing the anti-T4-B antibody. The incubation time was 30 minutes in a volume of 100 pL per well, and the membrane was not blocked with BSA. The results of the following conditions tested are shown in FIG. 19:
[0187] Well 1: 15 ng of T4-BSA + 2 pg of anti-T4-B antibody / 100 pL + secondary anti-T4 antibody (335 ng).
[0188] Well 2: 15 ng of T4-BSA + 10 pg of anti-T4-B antibody / 100 pL + secondary anti-T4 antibody (335 ng).
[0189] Well 3: 1 pg of T4-BSA + 2 pg of anti-T4-B antibody / 100 pL + anti-T4 secondary antibody (335 ng).
[0190] Well 4: 1 pg BSA + 2 pg anti-T4-B antibody / 100 pL + anti-T4 secondary antibody (335 ng).
[0191] Well 5: 1 pg T4-BSA + 300 nm latex particles (1%) - anti-T4 secondary antibody (335 ng).
[0192] Well 6: 15 ng T4-BSA + 2 pg of anti-T4-B antibody / 100 pL without anti-T4 secondary antibody (335 ng).
[0193] Well 7: Secondary anti-T4 antibody (335 ng) attached to membrane.
[0194] In FIG. 19 three columns can be seen, the first two columns correspond to the incubation wells of the anti-T4-B antibody with T4-BSA, and the third column is the development of the nitrocellulose membrane by dot-blot. The first column shows a photograph of the well after 30 minutes of incubation with the anti-T4-B, the second column shows the photograph of the same well after the nitrocellulose membrane was washed and dried. Agglutination can be observed in the second column in well 2, in which 15 ng of T4-BSA were incubated with 10 pg of the anti-T4-B antibody. In the second column of well 3, in which 1 pg T4-BSA was incubated with 2 pg of anti-T4-B, no agglutination is observed. Wells 4 and 5 are negative controls, well 6 is a negative control for secondary antibody specificity, and well 7 is a positive control for secondary antibody signal.
[0195] Example 8: Proficiency tests at 15 ng of T4.
[0196] To test whether the components of the low T4 detection device can discriminate between T4 levels less than 15 ng and greater than 15 ng, competition tests were performed. The conditions tested were as follows (FIG. 20):
[0197] Well 1: 15 ng of T4-BSA + 10 pg of anti-T4-B antibody / 100 μl + secondary anti-T4 antibody (335 ng).
[0198] Well 2: 15 ng of T4-BSA + 10 pg of anti-T4-B antibody / 100 pL + 15 ng of T4S + secondary anti-T4 antibody (335 ng).
[0199] Well 3: 15 ng of T4-BSA + 10 pg of anti-T4-B antibody / 100 pL + 30 ng of T4S + secondary anti-T4 antibody (335 ng).
[0200] Well 4: 15 ng of T4-BSA + 300 nm latex particles (1%) + anti-T4 secondary antibody (335 ng).
[0201] Well 5: 15 ng of T4-BSA + 2 pg of anti-T4-B antibody / 100 μl without anti-T4 secondary antibody (335 ng).
[0202] Pot 6: 1 pg BSA + 10 pg anti-T4-B antibody / 100 pl + anti-T4 secondary antibody (335 ng).
[0203] Well 7: Membrane-attached anti-T4 secondary antibody (335 ng).
[0204] Pot 8: 15 ng of T4-BSA + 5 pg of anti-T4-B antibody / 100 pl + anti-T4 secondary antibody (335 ng).
[0205] Pot 9: 15 ng of T4-BSA + 5 pg of anti-T4-B antibody / 100 pl + 15 ng of T4 + anti-T4 secondary antibody (335 ng).
[0206] The results obtained are shown in FIG. 20: three columns, the first three rows correspond to two wells that are duplicates of each other from the incubation of the anti-T4-B antibody with T4-BSA, and the third column corresponds to the development of the nitrocellulose membrane by the dot-blot methodology. The first column shows a photograph of the two wells at 30 minutes of incubation with the anti-T4-B. The second column shows photographs of the same two wells after the nitrocellulose membrane was washed and dried. Wells 1 correspond to the incubation of 10 pg of anti-T4-B with 15 ng of T4-BSA without T4S. Wells 2 and 3 correspond to the preincubation of 10 pg of anti-T4-B with 15 ng and 30 ng of T4S respectively, and then incubating them with 15 ng of T4-BSA that is adhered to the nitrocellulose membrane.Visual agglutination can be observed when 10 pg of anti-T4B antibody is incubated with T4-BSA when there is no T4S (well 1) and when T4S is at 15 ng (well 2). When incubated with 15 ng of T4S and 30 ng of T4S (well 2) it was expected to see competition, that is, no agglutination, however, agglutination is observed which implies that there is excess of antibody (well 3). Well 8 corresponds to the incubation of 5 pg of anti-T4-B with 15 ng of T4-BSA and as expected, agglutination was observed. In well 9, which corresponds to the preincubation of 5 pg of the anti-T4-B antibody with 15 ng of T4S and then the incubation with 15 ng of the T4-BSA conjugate that is adhered to the nitrocellulose membrane, agglutination was observed with respect to 10 pg of anti-T4-B. Wells 4, 5 and 6 correspond to negative controls and well 7 to positive control.
[0207] Example 9: Protocol for samples of more than 15 ng of T4.
[0208] The protocol was modified using a smaller incubation volume (50 µl) to simulate the volume of anti-T4-B antibody that will be present on the corresponding pad of the device, thus improving competition with T4S and therefore the discrimination of T4S amounts greater than 15 ng. For this study, the conditions tested were as follows (FIG. 21):
[0209] Well 1: 15 ng of T4-BSA + 5 pg of anti-T4-B antibody / 50 μl + anti-T4 secondary antibody (335 ng).
[0210] Well 2: 15 ng of T4-BSA + 10 pg of anti-T4-B antibody / 50 μl + secondary anti-T4 antibody (335 ng). Well 3: 15 ng of T4-BSA + 5 pg of anti-T4-B antibody / 50 μl + 5 ng of T4 + secondary anti-T4 antibody (335 ng).
[0211] Well 4: 15 ng of T4-BSA + 5 pg of anti-T4-B antibody / 50 μl + 15 ng of T4 + secondary anti-T4 antibody (335 ng).
[0212] Pot 5: 15 ng T4-BSA + 5 pg anti-T4-B / 50 pl antibody + 30 ng T4 + anti-T4 secondary antibody (335 ng).
[0213] Pot 6: 15 ng of T4-BSA + 10 pg of anti-T4-B antibody / 50 pl + 5 ng of T4 + anti-T4 secondary antibody (335 ng).
[0214] Pot 7: 15 ng of T4-BSA + 10 pg of anti-T4-B antibody / 50 pl + 15 ng of T4 + anti-T4 secondary antibody (335 ng).
[0215] Pot 8: 15 ng T4-BSA + 10 pg anti-T4-B antibody / 50 pL + 30 ng T4 + anti-T4 secondary antibody (335 ng).
[0216] Pot 9: 15 ng of T4-BSA + 300 nm latex particles (1 %) + anti-T4 secondary antibody (335 ng).
[0217] Pot 10: 15 ng of T4-BSA + 5 pg of anti-T4-B antibody without anti-T4 secondary antibody (335 ng).
[0218] Pot 1 1 : 1 pg BSA + 5 pg anti-T4-B antibody + anti- T4 secondary antibody (335 ng).
[0219] Well 12: Secondary anti-T4 antibody (335 ng) attached to membrane.
[0220] In FIG. 21 the results obtained are observed: three columns, the first two columns correspond to two wells that are duplicates of each other from the incubation of the anti-T4-B antibody with T4-BSA and the third column corresponds to the development of the nitrocellulose membrane by the dot-blot methodology. The first column shows a photograph of the two wells at 30 minutes of incubation with the anti-T4-B. The second column shows photographs of the same two wells after the nitrocellulose membrane was washed and dried. In wells 1 to 2, in which 5 pg of anti-T4-B are exposed only to T4-BSA, agglutination is observed, which corresponds to what was expected. In wells 3 to 5, 5 pg of anti-T4-B was incubated with 15 ng of T4-BSA and increasing amounts of T4S: 5 ng, 10 ng, and 30 ng, respectively. It can be seen that both the 15 ng and 30 ng of T4S competed with T4-BSA, and no agglutination was observed.However, agglutination is observed with 5 ng of T4S (well 3). On the other hand, when using 10 pg of anti-T4-B, both with 5 ng, 15 ng and 30 ng of T4S, agglutination is still observed in the membrane (points 6, 7 and 8), therefore, it is not possible to differentiate normal and deficient amounts of T4 in urine. In summary, using 5 pg of anti-T4-B and not 1 pg of anti-T4B it is possible to visualize the discrimination between amounts of T4S greater than 15 ng from those less than this value. This last finding is essential since it provides guidance on the amount of anti-T4-B that should be included in the corresponding pad in order to discriminate between a urine sample with normal ranges from a sample with T4 hormone deficiency.
[0221] Example 10: Validation of free T4 detection in urine samples from pregnant women.
[0222] To validate and correlate the data obtained from the device tests, thyroid profiles were determined using blood samples from pregnant volunteer patients recruited at the Family Health Centers (CESFAM) in the El Bosque commune (Santiago, Chile). The blood samples were sent to the Institute for Advanced Medical Studies (IEMA). The T4 deficiency discrimination system was then evaluated by dot-blot using urine samples from the same pregnant women whose thyroid profiles were measured in blood samples. For this purpose, six urine samples were preincubated with the anti-T4-B antibody and then added to the membrane and developed using the secondary antibody. The conditions tested for this study are described below, the results of which are shown in FIG. 22.
[0223] Point 1 : 15 ng of T4-BSA + 20 pg of anti-T4-B antibody + 0 ng of T4 + anti-T4 secondary antibody (335 ng).
[0224] Point 2: 15 ng of T4-BSA + 20 pg of anti-T4-B antibody + 10 ng of T4 + anti-T4 secondary antibody (335 ng).
[0225] Point 3: 15 ng of T4-BSA + 20 pg of anti-T4-B antibody + 13 ng of T4 + anti-T4 secondary antibody (335 ng). Point 4: 15 ng of T4-BSA + 20 pg of ant¡-T4-B antibody + 15 ng of T4 + anti-T4 secondary antibody (335 ng).
[0226] Point 5: 15 ng of T4-BSA + 20 pg of anti-T4-B antibody + 1 urine sample + anti-T4 secondary antibody (335 ng).
[0227] Point 6: 15 ng of T4-BSA + 20 pg of anti-T4-B antibody + urine sample 2 + anti-T4 secondary antibody (335 ng).
[0228] Point 7: 15 ng of T4-BSA + 20 pg of anti-T4-B antibody + urine sample 3 + anti-T4 secondary antibody (335 ng).
[0229] Item 8: 15 ng T4-BSA + 20 pg anti-T4-B antibody + urine sample 4 + anti-T4 secondary antibody (335 ng).
[0230] Item 9: 15 ng T4-BSA + 20 pg anti-T4-B antibody + urine sample 5 + anti-T4 secondary antibody (335 ng).
[0231] Item 10: 15 ng T4-BSA + 20 pg anti-T4-B antibody + urine sample 6 + anti-T4 secondary antibody (335 ng).
[0232] Point 11: 1 pg BSA + 20 pg anti-T4-B antibody + anti-T4 secondary antibody (335 ng).
[0233] Point 12: 15 ng T4-BSA + 0.1% BSA in TBS-T + anti-T4 secondary antibody (335 ng).
[0234] Item 13: 15 ng T4-BSA + 20 pg anti-T4-B antibody + TBS-T 0.1% BSA
[0235] Point 14: Secondary anti-T4 antibody (335 ng).
[0236] Table 1 shows the free T4 (FT4) and TSH values measured by the clinical laboratory in blood samples from patients whose samples were used for the assay in FIG. 22. All patients (1 - 6) had TSH and FT4 levels within the normal range, which is consistent with the result obtained in FIG. 15, in which no binding of the anti-T4-B antibody to T4-BSA is observed because all the antibody is bound to the T4 in the urine. Thus, it was mathematically calculated that under the detection conditions tested, 16.6% false positives and 83.3% correspondence with the clinical laboratory determination are observed, which validates that the system for detecting T4 deficiency in urine from pregnant women is sensitive, discriminatory, and correlates with the blood levels obtained for the patients studied.
[0237] Table 1. Thyroid physiological parameters of each pregnant woman included in the study.
Claims
CLAIMS 1. A device to detect levels below normal values of the T4 hormone during pregnancy in a urine sample, including: (a) a test strip made of an absorbent material that includes along its length reagents necessary to detect levels of the T4 hormone below a threshold; and (b) means for providing a visible readout in the form of a detection mark at levels of the T4 hormone below said threshold; CHARACTERIZED because said reagents include: - a conjugate of the T4 hormone with bovine serum albumin (T4-BSA); - a primary monoclonal antibody against the T4 hormone (anti-T4) bound to latex beads; and where the means for providing a visible readout in the form of a detection label at levels of the T4 hormone below said threshold is the formation of an immunocomplex between the primary monoclonal antibody against the T4 hormone (anti-T4) bound to latex beads and the T4 hormone present in the T4-BSA conjugate.
2. The device of claim 1, CHARACTERIZED in that said threshold is set at a concentration of the T4 hormone of 30 ng / ml of urine.
3. The device of claim 1, CHARACTERIZED in that the T4-BSA conjugate is present in the test strip at an amount between 10 - 15 ng.
4. The device of claim 1, CHARACTERIZED in that the anti-T4 primary monoclonal antibody detects up to 10 ng of the T4 hormone in 0.5 ml of the urine sample.
5. The device of any of the preceding claims, CHARACTERIZED in that said primary anti-T4 monoclonal antibody is It is bound to said latex spheres in a ratio of 2 mg / ml to 1% w / v of spheres.
6. The device of any of the preceding claims, CHARACTERIZED in that the latex spheres to which said primary anti-T4 monoclonal antibody binds are selected from the group consisting of colored, carboxylated, fluorescent and paramagnetic latex microspheres and have a size equal to or less than 0.3 pm.
7. The device of any of the preceding claims, CHARACTERIZED in that said primary anti-T4 monoclonal antibody bound to the latex spheres is present on the test strip at an amount of 5 - 10 pg.
8. A kit for detecting levels below normal values of the T4 hormone during pregnancy in a urine sample, CHARACTERIZED in that it comprises: (a) a device as described in any one of claims 1 to 7; and (b) written instructions on how to place the urine sample on the test strip of said device, and how to interpret the results observed from the appearance of the detection mark on said test strip.
9. A method for detecting levels below normal values of the T4 hormone during pregnancy in a urine sample, CHARACTERIZED in that it comprises the steps of: (a) providing a device as described in any one of claims 1 to 7 or a kit as described in claim 8; (b) add the urine sample to be analyzed to the test strip of said device; and (c) read the visible result on the strip as a detection mark, which is indicative of the pregnant woman from whom it was obtained This urine sample shows levels of the T4 hormone below 30 ng / ml.
10. The method of claim 9, CHARACTERIZED in that 0.5 ml of urine sample to be analyzed is added to the test strip of said device. 1 1. A method for the manufacture of a device for detecting levels below normal values of the T4 hormone during pregnancy in a urine sample, comprising: (c) provide a test strip made of an absorbent material; (d) placing along the length of the test strip the reagents necessary to detect levels of the T4 hormone below a threshold; and (e) provide means for visible reading of a detection mark corresponding to levels of the T4 hormone below said threshold; CHARACTERIZED because said reagents include: - a conjugate of the T4 hormone with bovine serum albumin (T4-BSA); - a primary monoclonal antibody against the T4 hormone (anti-T4) bound to latex beads; and where the means for providing a visible readout in the form of a detection label at levels of the T4 hormone below said threshold is the formation of an immunocomplex between the primary monoclonal antibody against the T4 hormone (anti-T4) bound to the latex beads and the T4 hormone present in the T4-BSA conjugate.
12. The method of claim 1 1, CHARACTERIZED in that the T4-BSA conjugate is added to the test strip in an amount between 10 - 15 ng.
13. The method of claims 1 or 12, CHARACTERIZED in that said primary anti-T4 monoclonal antibody is mixed with said latex spheres in a ratio of 2 mg / ml to 1% w / v of spheres.
14. The method of any of claims 11 to 13, CHARACTERIZED in that the latex spheres to which said primary anti-T4 monoclonal antibody binds are selected from the group consisting of colored, carboxylated, fluorescent and paramagnetic latex microspheres and are selected for a size equal to or less than 0.3 pm.
15. The method of any of claims 11 to 14, CHARACTERIZED in that said primary anti-T4 monoclonal antibody bound to the latex spheres is added to the test strip at an amount of 5 - 10 pg.
Citation Information
Patent Citations
Tetraiodothyroxide test kit and use method thereof
CN101865916B
Method for determining thyroxine uptake
EP0298708B1
